Quality of life in patients aged 65 years and older with overactive bladder treated with mirabegron across eight European countries: Secondary analysis of BELIEVE
| Autor: | Jameel Nazir, Anny Stari, Moses Huang, Nurul Choudhury, Robert Freeman, Stephen Foley |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Adult
Male medicine.medical_specialty Adolescent Urology 030232 urology & nephrology Adrenergic beta-3 Receptor Agonists 03 medical and health sciences Young Adult 0302 clinical medicine Quality of life Older patients Secondary analysis Internal medicine Surveys and Questionnaires Medicine Humans In patient Prospective Studies Aged Aged 80 and over Urinary bladder Per protocol set business.industry Urinary Bladder Overactive Age Factors Middle Aged medicine.disease Europe Thiazoles medicine.anatomical_structure Treatment Outcome Overactive bladder 030220 oncology & carcinogenesis Quality of Life Acetanilides Female business Mirabegron medicine.drug Follow-Up Studies |
| Zdroj: | International journal of urology : official journal of the Japanese Urological AssociationReferences. 26(9) |
| ISSN: | 1442-2042 |
| Popis: | OBJECTIVES To describe quality of life outcomes in patients with overactive bladder aged ≥65 years receiving mirabegron, a β3-adrenoreceptor agonist (BELIEVE). METHODS BELIEVE was a European, prospective, non-interventional, real-world study of 848 patients with overactive bladder prescribed mirabegron in clinical practice. Overactive bladder questionnaire subscales were prespecified primary end-points, analyzed in the full analysis set (patients completing the questionnaire at baseline and ≥1 follow-up visit) and per protocol set (patients still taking mirabegron at 10-12 months) using accepted standards for minimally important differences (10 points). RESULTS Nearly half of the patients in the full analysis set (380/796 [47.7%]) and per protocol set (224/452 [49.6%]) were aged ≥65 years. Similar proportions of patients aged ≥65 years (224/407; 55.0%) and |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text